Every 8-K that Enanta Pharmaceuticals, Inc (ENTA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ENTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENTA filings page.
Enanta Pharmaceuticals, Inc. reported fiscal third quarter 2026 results, reflecting a clinical-stage company investing heavily in virology and immunology while posting continued losses. Revenue for the quarter was $14.4 million, all from royalties on AbbVie’s HCV regimen MAVYRET®/MAVIRET®, down from $18.3 million a year earlier due to lower HCV sales.
Research and development expenses fell to $22.1 million and general and administrative expenses to $9.5 million, helping limit the quarterly net loss to $19.5 million, or $0.67 per diluted share. Cash, cash equivalents and marketable securities totaled $211.5 million at June 30, 2026, and the company expects this, along with retained royalties, to fund operations into fiscal 2029. Enanta highlighted progress in its RSV program, including dosing initiation in the Phase 2b pediatric LOTUS trial of zelicapavir and preparation for RESOLVE, a registrational Phase 2b/3 trial in high-risk adults, with topline data from both expected in 2027. It also advanced immunology candidates EDP-978 (KIT inhibitor), EPS-3903 (STAT6 inhibitor) and MRGPRX2-targeting compounds, and noted European Commission approval of MAVIRET for acute HCV, which supports ongoing royalty revenue.
Enanta Pharmaceuticals entered an Open Market Sale Agreement with Jefferies LLC that allows it to sell up to $75,000,000 of common stock from time to time through an at-the-market program. Shares will be issued under Enanta’s effective Form S-3 shelf registration and a July 2, 2026 prospectus supplement.
Jefferies will act as sales agent and use commercially reasonable efforts to place shares on Nasdaq or other markets, earning a commission of up to 3.0% of the gross sales price per share. Enanta is not obligated to sell any shares, and the arrangement can be terminated in accordance with the agreement’s terms.
Enanta Pharmaceuticals, Inc. reported that the United States Court of Appeals for the Federal Circuit has affirmed a prior summary judgment ruling in its patent case against Pfizer Inc. The Federal Circuit ruled that the claims of Enanta’s U.S. Patent No. 11,358,953, related to Pfizer’s COVID-19 antiviral Paxlovid, are invalid, effectively upholding the December 2024 decision from the U.S. District Court for the District of Massachusetts.
Enanta Pharmaceuticals is advancing its RSV antiviral zelicapavir into a single registrational Phase 2b/3 trial in high-risk adult outpatients after a successful End-of-Phase 2 FDA meeting. The Phase 2b portion will enroll at least 200 patients, with approximately 660 more in Phase 3, and topline Phase 2b data expected in 2027.
The company also plans a Phase 2b pediatric trial in children 28 days to 36 months old, starting in the third quarter of 2026, with topline data also expected in 2027. Earlier Phase 2 data showed clinically meaningful improvements, including a 6.7-day faster symptom resolution and lower RSV-related hospitalizations in high-risk adults, and antiviral and symptom benefits in children.
Zelicapavir, an RSV N-protein inhibitor with FDA Fast Track designation, has been well tolerated in more than 700 subjects. Enanta estimates an oral RSV antiviral for children and high-risk adults represents a global opportunity of over $2 billion, with a potential U.S. addressable population greater than 3 million patients.
Enanta Pharmaceuticals, Inc. reported results from its March 11, 2026 annual meeting. Stockholders approved an amendment to the 2019 Equity Incentive Plan, increasing the shares of common stock reserved for issuance by 1,600,000 shares.
Two Class I directors, Bruce L.A. Carter, Ph.D., and Jay R. Luly, Ph.D., were re-elected to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, the compensation of named executive officers and ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026.
Enanta Pharmaceuticals reported a narrower net loss for its fiscal first quarter ended December 31, 2025 while advancing its RSV and immunology pipelines. Revenue rose to $18.6 million from $17.0 million, driven by higher royalties on AbbVie’s MAVYRET®/MAVIRET® hepatitis C treatment.
Research and development expense fell to $20.9 million from $27.7 million and general and administrative expense declined to $9.0 million from $12.8 million, reflecting lower clinical, stock-based compensation and legal costs. Net loss improved to $11.9 million, or $0.42 per diluted share, from $22.3 million, or $1.05 per diluted share.
Enanta ended the quarter with $241.9 million in cash, cash equivalents and marketable securities and expects this, plus its retained portion of future royalty revenue, to fund operations into fiscal 2029. The company is conducting Phase 3 enabling work for RSV candidate zelicapavir, progressing RSV drug EDP-323, and advancing three immunology programs, including KIT inhibitor EDP-978 and STAT6 inhibitor EPS-3903, with multiple planned IND filings and data milestones in 2026.
Enanta Pharmaceuticals, Inc. (ENTA) filed a current report to announce that it released a press release with its financial results for the fiscal quarter and year ended September 30, 2025. The press release, dated November 17, 2025, is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed numbers and commentary are contained in that exhibit rather than in the body of this report. This filing is a standard earnings disclosure under Item 2.02 of the Exchange Act.
Enanta Pharmaceuticals reported a material event in an 8-K that discloses an Underwriting Agreement dated September 30, 2025, legal opinion and consent from Foley Hoag LLP, and an embedded interactive cover page XBRL file. The filing restates standard forward-looking statement disclaimers and indicates the company will not update forward-looking statements except as required by law. The document is signed by Jay R. Luly, Ph.D., President and Chief Executive Officer, with a filing date of October 1, 2025.
Enanta Pharmaceuticals reported that it has positive topline results from a Phase 2b study of its drug candidate zelicapavir (formerly EDP-938) in high-risk adults with respiratory syncytial virus (RSV). This mid-stage trial focuses on adults who are more likely to develop serious RSV disease, so encouraging data at this stage can be important for deciding whether to move the program into later-stage studies.
To share more detail, the company prepared a slide deck titled “Phase 2b Study of Zelicapavir in High-Risk Adults: RSVHR Topline Results,” which is included as an exhibit to this report. The presentation is being furnished rather than filed, which limits how it is treated under certain securities law liability provisions, but it provides investors with an overview of the initial clinical findings for zelicapavir in RSV.
Enanta Pharmaceuticals filed an Form 8-K reporting a proof-of-concept, signal-finding study of oral antiviral zelicapavir for RSV. Patients were enrolled within 72 hours of symptom onset and received 800mg once daily for 5 days or placebo. The trial measured symptoms using the RiiQTM scale covering 13 RSV symptoms and assessed a four-symptom lower respiratory tract disease (LRTD) subset as the primary endpoint, defined as time to resolution to mild, with predefined complete-resolution analyses also conducted. Secondary measures included total RiiQTM score, patient global impressions, virology, safety, and hospitalization rate. The filing references the company’s 2024 10-K and includes the company caution on forward-looking statements. The 8-K is signed by Jay R. Luly, Ph.D. and dated September 29, 2025.
Enanta Pharmaceuticals reported temporary changes in its finance leadership. On August 26, 2025, the board named Harry R. Trout, III, the company’s Vice President of Finance, as interim principal financial officer and Kathleen (“Katie”) S. Capps, CPA, Executive Director, Accounting & Controller, as interim principal accounting officer. These appointments are explicitly described as interim while Chief Financial and Administrative Officer Paul J. Mellett is on a medical leave of absence and will continue until he is able to resume his roles. The company notes that Trout and Capps have long tenures in accounting and finance roles, will be eligible for standard indemnification agreements, and have not entered into any new material compensation or other arrangements in connection with these interim appointments. The filing also states there are no family relationships or related-party transactions involving either executive that require disclosure.
Enanta Pharmaceuticals, Inc. filed a current report describing new patent litigation related to COVID-19 treatments. On August 20, 2025, Enanta announced it filed a suit in the Unified Patent Court of the European Union against Pfizer Inc. and certain subsidiaries.
The action seeks a determination of liability for alleged use and infringement of European Patent No. EP 4 051 265 in connection with the manufacture, use and sale of Pfizer’s COVID-19 antiviral Paxlovid (nirmatrelvir tablets; ritonavir tablets) across 18 participating EU countries. The patent, granted and published on August 20, 2025, stems from Enanta’s July 2020 coronavirus protease inhibitor work and is the European counterpart to a U.S. patent already in related U.S. litigation between the companies.
Enanta Pharmaceuticals, Inc. filed a Form 8-K to report that it has announced its financial results for the fiscal quarter ended June 30, 2025. On August 11, 2025, the company issued a press release with these quarterly results and furnished that release as Exhibit 99.1. The filing is primarily administrative, directing readers to the press release for detailed financial information, and is signed on behalf of the company by President and Chief Executive Officer Jay R. Luly, Ph.D.